"These four patients are heroes," said study's principal investigator, pediatric neuro-oncologist Michelle Monje, MD, PhD. Though all the trial patients died of their disease or its complications, three of them experienced significant clinical benefits from the engineered cells. He was one of the first four patients with diffuse intrinsic pontine glioma or a closely related cancer affecting the spinal cord to receive immune cells engineered to fight the disease. Today a group of Stanford scientists who have spent the past decade unlocking the glioma's secrets are publishing data in Naturefrom the trial Ward joined. The disease has a five-year survival rate of less than one percent. His diagnosis was diffuse intrinsic pontine glioma, or DIPG, which conventional cancer treatments can't cure. When Jace Ward came to Lucile Packard Children's Hospital Stanford in September 2020 to join a clinical trial for a novel therapy, he had been fighting a deadly brainstem tumor for more than a year.
0 kommentar(er)
